INOVIO PHARMACEUTICALS, INC. Quarterly Operating Income (Loss) in USD from Q2 2010 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Inovio Pharmaceuticals, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q2 2010 to Q3 2024.
  • Inovio Pharmaceuticals, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$27.3M, a 23.1% increase year-over-year.
  • Inovio Pharmaceuticals, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$119M, a 30.8% increase year-over-year.
  • Inovio Pharmaceuticals, Inc. annual Operating Income (Loss) for 2023 was -$144M, a 46.2% increase from 2022.
  • Inovio Pharmaceuticals, Inc. annual Operating Income (Loss) for 2022 was -$268M, a 11.2% increase from 2021.
  • Inovio Pharmaceuticals, Inc. annual Operating Income (Loss) for 2021 was -$301M, a 143% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$119M -$27.3M +$8.21M +23.1% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-14
Q2 2024 -$128M -$33.2M +$3.84M +10.4% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 -$131M -$31.5M +$12.5M +28.4% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-13
Q4 2023 -$144M -$27.4M +$28.6M +51% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-06
Q3 2023 -$172M -$35.6M +$204K +0.57% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 -$173M -$37M +$67.1M +64.4% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 -$240M -$44M +$27.8M +38.7% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-13
Q4 2022 -$268M -$55.9M +$49.6M +47% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-06
Q3 2022 -$317M -$35.8M +$24.2M +40.4% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$341M -$104M -$20.9M -25.2% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-09
Q1 2022 -$320M -$71.7M -$19.2M -36.5% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-10
Q4 2021 -$301M -$106M -$76.2M -260% Oct 1, 2021 Dec 31, 2021 10-K 2024-03-06
Q3 2021 -$225M -$60M -$23.6M -65% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 -$201M -$83.2M -$50M -151% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 -$151M -$52.6M -$27.3M -108% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q4 2020 -$124M -$29.3M +$1.08M +3.56% Oct 1, 2020 Dec 31, 2020 10-K 2021-03-01
Q3 2020 -$125M -$36.3M -$12.4M -51.7% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-09
Q2 2020 -$113M -$33.2M -$4.98M -17.7% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-09
Q1 2020 -$108M -$25.2M +$3.3M +11.6% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-10
Q4 2019 -$111M -$30.4M -$922K -3.13% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-01
Q3 2019 -$110M -$24M +$2.69M +10.1% Jul 1, 2019 Sep 30, 2019 10-K 2021-03-01
Q2 2019 -$113M -$28.2M -$23M -442% Apr 1, 2019 Jun 30, 2019 10-K 2021-03-01
Q1 2019 -$89.9M -$28.5M +$4.21M +12.9% Jan 1, 2019 Mar 31, 2019 10-K 2021-03-01
Q4 2018 -$94.1M -$29.5M -$6.61M -28.9% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-12
Q3 2018 -$87.5M -$26.6M +$2.54M +8.71% Jul 1, 2018 Sep 30, 2018 10-K 2020-03-12
Q2 2018 -$90M -$5.2M +$4.43M +46% Apr 1, 2018 Jun 30, 2018 10-K 2020-03-12
Q1 2018 -$94.5M -$32.7M -$10.8M -49.3% Jan 1, 2018 Mar 31, 2018 10-K 2020-03-12
Q4 2017 -$83.6M -$22.9M -$524K -2.35% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-12
Q3 2017 -$83.1M -$29.2M -$8.99M -44.5% Jul 1, 2017 Sep 30, 2017 10-K 2019-03-12
Q2 2017 -$74.1M -$9.64M +$8.59M +47.1% Apr 1, 2017 Jun 30, 2017 10-K 2019-03-12
Q1 2017 -$82.7M -$21.9M -$6.48M -42% Jan 1, 2017 Mar 31, 2017 10-K 2019-03-12
Q4 2016 -$76.2M -$22.4M -$7.84M -53.9% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-14
Q3 2016 -$68.4M -$20.2M -$23.9M -641% Jul 1, 2016 Sep 30, 2016 10-K 2018-03-14
Q2 2016 -$44.5M -$18.2M -$3.11M -20.5% Apr 1, 2016 Jun 30, 2016 10-K 2018-03-14
Q1 2016 -$41.4M -$15.5M -$7.08M -84.6% Jan 1, 2016 Mar 31, 2016 10-K 2018-03-14
Q4 2015 -$34.3M -$14.5M -$3.51M -31.9% Oct 1, 2015 Dec 31, 2015 10-K 2017-03-15
Q3 2015 -$30.8M $3.73M +$12.1M Jul 1, 2015 Sep 30, 2015 10-K 2017-03-15
Q2 2015 -$42.8M -$15.1M -$4.97M -48.9% Apr 1, 2015 Jun 30, 2015 10-K 2017-03-15
Q1 2015 -$37.9M -$8.37M +$1.63M +16.3% Jan 1, 2015 Mar 31, 2015 10-K 2017-03-15
Q4 2014 -$39.5M -$11M -$3.01M -37.6% Oct 1, 2014 Dec 31, 2014 10-K 2016-03-14
Q3 2014 -$36.5M -$8.33M -$9.1M -1188% Jul 1, 2014 Sep 30, 2014 10-K 2016-03-14
Q2 2014 -$27.4M -$10.2M -$4.48M -79% Apr 1, 2014 Jun 30, 2014 10-K 2016-03-14
Q1 2014 -$22.9M -$10M -$3.37M -50.7% Jan 1, 2014 Mar 31, 2014 10-K 2016-03-14
Q4 2013 -$19.5M -$8M -$1.78M -28.5% Oct 1, 2013 Dec 31, 2013 10-K 2015-03-16
Q3 2013 -$17.8M $766K +$7.06M Jul 1, 2013 Sep 30, 2013 10-K 2015-03-16
Q2 2013 -$24.8M -$5.67M +$1.12M +16.4% Apr 1, 2013 Jun 30, 2013 10-K 2015-03-16
Q1 2013 -$25.9M -$6.63M -$2.45M -58.5% Jan 1, 2013 Mar 31, 2013 10-K 2015-03-16
Q4 2012 -$23.5M -$6.23M -$447K -7.74% Oct 1, 2012 Dec 31, 2012 10-K 2014-03-17
Q3 2012 -$23M -$6.29M +$44.5K +0.7% Jul 1, 2012 Sep 30, 2012 10-K 2014-03-17
Q2 2012 -$23.1M -$6.79M -$1.65M -32.1% Apr 1, 2012 Jun 30, 2012 10-K 2014-03-17
Q1 2012 -$21.4M -$4.19M +$199K +4.54% Jan 1, 2012 Mar 31, 2012 10-K 2014-03-17
Q4 2011 -$21.6M -$5.78M Oct 1, 2011 Dec 31, 2011 10-K 2013-03-18
Q3 2011 -$6.34M -$1.78M -39.1% Jul 1, 2011 Sep 30, 2011 10-K 2013-03-18
Q2 2011 -$5.14M -$161K -3.23% Apr 1, 2011 Jun 30, 2011 10-K 2013-03-18
Q1 2011 -$4.39M Jan 1, 2011 Mar 31, 2011 10-K 2013-03-18
Q3 2010 -$4.56M Jul 1, 2010 Sep 30, 2010 10-Q 2011-11-07
Q2 2010 -$4.98M Apr 1, 2010 Jun 30, 2010 10-Q 2011-08-05
* An asterisk sign (*) next to the value indicates that the value is likely invalid.